Targeted therapies in interstitial lung disease secondary to systemic autoimmune rheumatic disease. Current status and future development

被引：10
|
作者：
Karakontaki, Foteini, V [1 ]
Panselinas, Efstratios S. [2 ]
Polychronopoulos, Vlasios S. [1 ]
Tzioufas, Athanasios G. [3 ]
机构：
[1] Hygeia Hosp, Dept Pulm Med, Athens, Greece
[2] Pulmonologist, Tripoli, Greece
[3] Univ Athens, Sch Med, Dept Pathophysiol, 75 M Asias St,Bldg 16,Room 32, Athens 11527, Greece
来源：
AUTOIMMUNITY REVIEWS | 2021年 / 20卷 / 02期
关键词：
Autoimmune rheumatic diseases; Interstitial lung disease; Rheumatoid arthritis; Sjogren's syndrome; Vasculitis; Myositis; Scleroderma immunosuppressive drugs; Targeted treatment; Anti-fibrotic treatment; CONNECTIVE-TISSUE DISEASE; ANTI-SYNTHETASE SYNDROME; PRIMARY SJOGRENS-SYNDROME; MYCOPHENOLATE-MOFETIL; OPEN-LABEL; RITUXIMAB THERAPY; IMATINIB MESYLATE; ARTHRITIS; SCLEROSIS; EFFICACY;
D O I：
10.1016/j.autrev.2020.102742
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Autoimmune rheumatic diseases (ARD) are characterized by systemic manifestations and multiple organ involvement, including the lung. Interstitial Lung Disease (ILD) is a cardinal manifestation of lung involvement in patients with ARD and is associated with significant morbidity and mortality. Corticosteroids and immunosuppressive drugs are used as first -line treatment. Targeted therapies, such as biological disease modifying anti-rheumatic drugs (DMARDS) and anti- fibrotic agents are new treatment options. In this review we discuss the role of targeted therapies in patients with ILD secondary to ARD.
引用
收藏
页数：7
相关论文
共 50 条
  • [31] Biomarker-driven development of new therapies for autoimmune diseases: current status and future promises
    Laigle, Laurence
    Chadli, Loubna
    Moingeon, Philippe
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2023, 19 (03) : 305 - 314
  • [32] Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases
    Perez-Alvarez, Roberto
    Perez-de-Lis, Marta
    Diaz-Lagares, Candid
    Pego-Reigosa, Jose M.
    Retamozo, Soledad
    Bove, Albert
    Brito-Zeron, Pilar
    Bosch, Xavier
    Ramos-Casals, Manuel
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2011, 41 (02) : 256 - 264
  • [33] Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies
    Volkmann, Elizabeth R.
    Tashkin, Donald P.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2016, 13 (11) : 2045 - 2056
  • [34] The Role of Nailfold Videocapillaroscopy in the Diagnosis and Monitoring of Interstitial Lung Disease Associated with Rheumatic Autoimmune Diseases
    Anghel, Daniela
    Prioteasa, Oana-Georgiana
    Nicolau, Iulia-Nadine
    Bucurica, Sandica
    Belinski, Daniela-Opris
    Popescu, Gilda-Georgeta
    Ghinescu, Minerva Claudia
    Bobirca, Anca
    Groseanu, Maria-Laura
    Bojinca, Violeta-Claudia
    DIAGNOSTICS, 2025, 15 (03)
  • [35] Anti-Ro52 Autoantibody Is Common in Systemic Autoimmune Rheumatic Diseases and Correlating with Worse Outcome when Associated with interstitial lung disease in Systemic Sclerosis and Autoimmune Myositis
    Edward K. L. Chan
    Clinical Reviews in Allergy & Immunology, 2022, 63 : 178 - 193
  • [36] ARGENTINE LONGITUDINAL REGISTRY OF AUTOIMMUNE INTERSTITIAL LUNG DISEASE. EPIMAR 2: BASELINE DATA OF THE FIRST 120 PATIENTS
    Vivero, Florencia
    Buschiazzo, Emilio
    Montoya, Fabiana
    Oliver, Marina
    De la Vega, Maria
    Zamora, J. Velasco
    Nistche, Alejandro
    Martin, Maria Luz
    Barbaglia, Ana
    Estel, Guillermo Pons
    Benitez, Alejandro
    Gordillo, Florencia
    Bersano, Noelia
    Lloves, Nicolas
    Paula, Gonzalo
    Pena, Claudia
    Gamarra, Antonella
    Martinez Munoz, Alejandro
    Pacheco, Gonzalo
    Natalia, Nigra
    Lopez Meiller, Maria Jose
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2023, 29 : S68 - S68
  • [37] Treatment of fibrotic interstitial lung disease: current approaches and future directions
    Johannson, Kerri A.
    Chaudhuri, Nazia
    Adegunsoye, Ayodeji
    Wolters, Paul J.
    LANCET, 2021, 398 (10309): : 1450 - 1460
  • [38] Prevalence and risk factors of non-tuberculous mycobacterial pulmonary isolates and infection in interstitial lung disease associated with systemic autoimmune disease
    Shu, C. -c.
    Chen, P. -s.
    Lin, Z. -h.
    Hsiao, C. -t.
    Kuo, C. -c.
    Chiang, H. -y.
    Wu, P. -c.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (05) : 1006 - 1014
  • [39] Pharmacological treatment of systemic sclerosis-associated interstitial lung disease: an updated review and current approach to patient care
    Mendoza, F. A.
    Allawh, T.
    Jimenez, S. A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (08) : 1704 - 1712
  • [40] Interstitial Lung Disease Worsens Short- and Long-Term Outcomes of Systemic Rheumatic Disease Patients Admitted to the ICU: A Multicenter Study
    Banuls, Lorrain
    Vanoverschelde, Juliette
    Garnier, Fanny
    Amalric, Matthieu
    Jaber, Samir
    Charbit, Jonathan
    Chalard, Kevin
    Mourad, Marc
    Benchabane, Nacim
    Benomar, Racim
    Besnard, Noemie
    Daubin, Delphine
    Brunot, Vincent
    Klouche, Kada
    Larcher, Romaric
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (05) : 1 - 11
12345